Dr. Willmar Schwabe GmbH & Co. KG engages in research, development, production, and distribution of generic drugs derived from plants. It offers herbal medicinal products, which include medicines for the treatment of memory loss, lack of concentration, anxiety, bronchitis, muscle and joint pain, enlarged prostate, neurodermatitis, eczemas, and sleeping problems. The company was founded by Willmar Schwabe in 1866 and is headquartered in Karlsruhe, Germany.

The Pasteur Institute of Lille (French: Institut Pasteur de Lille, Pasteur-Lille, IPL) is a research centre and member of the Pasteur Institute network. It includes 14 research units and 1,150 employees including 626 researchers located in Lille, France. There are also 300 employees located outside the Pasteur site. Its revenues are above €70 million. Several neuroscience start-up companies have emerged from the Pasteur Institute of Lille.

TriStrata develops encryption software that safeguards information and communications transmitted over a company's computer network.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Tulane Educational Fund is a private company headquartered in the United States specializing in radio broadcasting stations.

Sankyo Pharma GmbH, a subsidiary of Daiichi Sankyo Co., Ltd., is a German company located in Munich. The firm distributes pharmaceuticals. Jan van Ruymbeke is the current CEO, occupying that position since 2012.

Hunter Immunology Ltd. operates as a biotechnology company. It develops immune modulators for treatment of respiratory diseases. The company was founded by Phillip Comans in 2003 and is headquartered in Victoria, Australia.

Kyoritsu Seiyaku Corp. engages in the research, development, and production of vaccines and drugs for pets, livestock, and marine animals. It also deals with the manufacture of industrial and general deodorizers. The company was founded on May 19, 1955 and is headquartered in Tokyo, Japan.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Shengda (Zhangjiakou) Pharmaceutical Co., Ltd., established on 2002-08-15, Business scope includes research and development,Manufacture and sale of tablets,hard capsule,Granules,Powder,oral suspension,Chinese herbal extract;research and development,Manufacture and sale of Class II medical devices:6863Dental materials,6864Medical and sanitary materials and accessories;research and development,Manufacture and sales of oral care products,Denture cleaning materials and plastics;research and development,Manufacture and sales of nutritional products and health food.(Restrictions on the National Catalog of Foreign Investment Industries,Except prohibited)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Ferrer Internacional SA engages in the development, manufacture and commercialization of pharmaceutical products for the diagnosis and treatment of cardiovascular, dermatological, gastrointestinal and respiratory conditions. It also designs and produces active ingredients and nutraceuticals for the food, cosmetics and animal feed industries. The company was founded on April 17, 1940 and is headquartered in Barcelona, Spain.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom.

PROGE FARM products are based on selected probiotic strains. PROGE FARM selects, develops, registers, and commercializes probiotic products for specific therapeutic areas like the gastrointestinal and gynecological environment. Those products are classified as medicines, medical devices, and food supplements.

Yakult Honsha Co., Ltd. engages in the manufacture and sale of food and beverage products, cosmetics, and pharmaceuticals. It operates through the following segments: Food and Beverages in Japan, the Americas, Asia and Oceania, and Europe; Pharmaceuticals, and Others. The Food and Beverages segment produces and merchandises milk drinks, noodles, juices, and soft drinks. The Pharmaceuticals segment manufactures and sells anti-cancer drugs and other pharmaceutical products. The Others segment includes cosmetics and professional baseball team management. The company was founded by Minoru Shirota in 1935 and is headquartered in Tokyo, Japan.

Dompé SpA provides services of updating and scientific assistance to doctors. It offers information on therapeutic areas including physiatrics, cystic fibrosis, geriatrics, infectious diseases, internal, sleep and sports medicine, odontology, orthopedics and traumatology, otorhinolaryngology, pediatrics, pneumology, and emergency and drugs. The company was founded by Sergio Dompé in 1993 and is headquartered in L'Aquila, Italy.

Mipharm was founded in January 1998 by Mr. Giuseppe G. Miglio, who can show more than 40 years of experience in the pharmaceutical world and in Sandoz Holding, where he covered many and growing positions. In 1986 he was appointed to President and Managing Director of Sandoz Prodotti Farmaceutici SpA ; in 1990 he was appointed President and Managing Director of Sandoz Holding Italia Spa. In 1996, he managed first the merger between Sandoz and Ciba Geigy and then he was appointed President of Novartis Italy, until he decided to found Mipharm, a new company that in few years has become an important player in pharmaceutical market both in Italy and in Europe. Mipharm acquired from Novartis the production site (former Sandoz facility) based in Milan: starting from its production capacity, many third party production agreements have been signed. Up to 2009, Mipharm developed an integrated business model based on a modern and efficient production site and on a Business Unit Promotion focused on sales & marketing of new and innovative products.